Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE Trial: Perioperative Stress Reduction in Ovarian Cancer
NCT05429970Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of propranolol and etodolac in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of participants successfully completing over 80% of the bundled interventions at 21 days. Started Jun 2022; status: recruiting.
02
Drugs
propranololetodolac
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05429970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429970.